Johnson & Johnson
JNJ · Pharmaceuticals
$263.81
1.4%Moderna
MRNA · Biotechnology
$200.10
1.2%The short version
- Johnson & Johnson is the larger business, with $94.2B of revenue in fiscal 2025 against $1.9B for Moderna, about 48 times as much.
- Johnson & Johnson grew revenue faster (6.1%, against −39.9%).
- Johnson & Johnson turned more of its sales into free cash flow (20.9% FCF margin, against −106.2% FCF margin).
- Johnson & Johnson earned a higher return on the capital invested in it (28.6%, against −65.4%).
| Latest fiscal year | JNJ · FY25 | MRNA · FY25 |
|---|---|---|
| Size | ||
| Market cap | $646.0B | $79.6B |
| Revenue | $94.2B | $1.9B |
| Free cash flow | $19.7B | −$2.1B |
| Net income | $26.8B | −$2.8B |
| Growth | ||
| Revenue growth | 6.1% | −39.9% |
| 5-year growth | 2.7% | 19.3% |
| Share count change | 0.0% | 1.3% |
| Profitability | ||
| Gross margin | 67.9% | 55.4% |
| Operating margin | — | −158.1% |
| Net margin | 28.5% | −145.2% |
| FCF margin | 20.9% | −106.2% |
| Return on capital | 28.6% | −65.4% |
| Return on equity | 35.0% | −28.9% |
| Balance sheet | ||
| Net debt | $27.8B | −$5.2B |
| Net debt / EBITDA | 0.7x | — |
| Dividends and buybacks | $18.3B | $2.0M |
| Valuation & quality | ||
| P/E | 40.0x | — |
| Piotroski F-score | 4 | 2 |
FY16
JNJ $71.9B
MRNA $108M
FY17
JNJ $76.5B
MRNA $206M
FY18
JNJ $81.6B
MRNA $135M
FY19
JNJ $82.1B
MRNA $60.0M
FY20
JNJ $82.6B
MRNA $803M
FY21
JNJ $78.7B
MRNA $18.5B
FY22
JNJ $80.0B
MRNA $19.3B
FY23
JNJ $85.2B
MRNA $6.8B
FY24
JNJ $88.8B
MRNA $3.2B
FY25
JNJ $94.2B
MRNA $1.9B
JNJ
MRNA
FY16
JNJ —
MRNA −206.4%
FY17
JNJ —
MRNA −130.9%
FY18
JNJ —
MRNA −306.0%
FY19
JNJ —
MRNA −910.0%
FY20
JNJ —
MRNA −95.0%
FY21
JNJ —
MRNA 72.0%
FY22
JNJ —
MRNA 48.9%
FY23
JNJ —
MRNA −61.9%
FY24
JNJ —
MRNA −121.9%
FY25
JNJ —
MRNA −158.1%
JNJ
MRNA
FY16
JNJ $15.5B
MRNA $33.6M
FY17
JNJ $17.8B
MRNA −$390M
FY18
JNJ $18.5B
MRNA −$437M
FY19
JNJ $19.9B
MRNA −$491M
FY20
JNJ $20.2B
MRNA $2.0B
FY21
JNJ $19.8B
MRNA $13.3B
FY22
JNJ $17.2B
MRNA $4.6B
FY23
JNJ $18.2B
MRNA −$3.8B
FY24
JNJ $19.8B
MRNA −$4.1B
FY25
JNJ $19.7B
MRNA −$2.1B
JNJ
MRNA
FY16
JNJ 31.7%
MRNA —
FY17
JNJ 14.1%
MRNA —
FY18
JNJ 22.0%
MRNA —
FY19
JNJ 22.2%
MRNA —
FY20
JNJ 21.1%
MRNA —
FY21
JNJ 24.0%
MRNA —
FY22
JNJ 19.5%
MRNA —
FY23
JNJ 16.5%
MRNA —
FY24
JNJ 18.5%
MRNA —
FY25
JNJ 28.6%
MRNA −65.4%
JNJ
MRNA
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.